Troy Edward Wilson Sells 10,800 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Edward Wilson sold 10,800 shares of Puma Biotechnology stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $7.20, for a total value of $77,760.00. Following the transaction, the director directly owned 59,750 shares in the company, valued at approximately $430,200. The trade was a 15.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Puma Biotechnology Trading Up 1.4%

NASDAQ:PBYI opened at $7.17 on Wednesday. The company has a 50-day moving average of $7.24 and a 200-day moving average of $6.58. The firm has a market cap of $364.95 million, a price-to-earnings ratio of 14.94 and a beta of 1.21. Puma Biotechnology, Inc. has a twelve month low of $3.03 and a twelve month high of $7.90.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.09. The business had revenue of $44.81 million during the quarter, compared to analyst estimates of $42.00 million. Puma Biotechnology had a net margin of 10.69% and a return on equity of 20.30%. On average, research analysts forecast that Puma Biotechnology, Inc. will post 0.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PBYI has been the subject of several research reports. Weiss Ratings lowered Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Royal Bank of Canada raised its position in Puma Biotechnology by 244.5% during the first quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 3,066 shares during the period. BNP Paribas Financial Markets boosted its position in Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 2,290 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Puma Biotechnology during the 4th quarter valued at about $49,000. State of Alaska Department of Revenue acquired a new position in shares of Puma Biotechnology in the 4th quarter valued at about $50,000. Finally, ProShare Advisors LLC acquired a new position in shares of Puma Biotechnology in the 4th quarter valued at about $60,000. 61.29% of the stock is owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.